Recent Updates
Recently added Catalysts

Mannatech, Incorporated

MTEXFDA catalysts, PDUFA dates & pipeline intelligence
$2.56
▲ +0.11 · +4.49%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MTEX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.3252W HIGH $9.97
Volume
10.21 K
Value Traded
26.82 K
Short % Float
1.47%
Days to Cover
1.0
-59.37%Week
-70.11%1 Month
-59.49%3 Month
-41.42%6 Month
-73.58%1 Year
-93.41%5 Year
-95.4%All Time

Cash Data

Unlock MTEX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.94 M
EPS (TTM)
-0.22
P/E Ratio
-
Ent. Value
2.47 M
Total Shares
1.93 M
Float Shares
780.00 K
Insiders
59.45%
Institutions
8.04%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every MTEX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MTEX Catalyst Timeline

Dated clinical, regulatory and corporate events for Mannatech, Incorporated

Catalyst Timeline

Dated clinical, regulatory & corporate events for Mannatech, Incorporated

146Total events
0Upcoming
1Tier-1 (high impact)
2004 to 2026Coverage

Event history 50

▼Quarterly UpdateCorporate
Mannatech reports third quarter 2026 financial results
▲Stock ListingCorporate
Nasdaq notified Mannatech it complies with minimum stockholders' equity requirement
●Restructuring LayoffsCorporate
Internal restructuring of certain foreign subsidiaries completed
●Quarterly UpdateCorporate
Mannatech reports second quarter 2026 financial results
◆Product LaunchPost-Market
Tiered affiliate program pre-launch for AMPM powders
▲Quarterly UpdateCorporate
Board declares Q1 2023 cash dividend of $0.20 per share
●Quarterly UpdateCorporate
Board declared Q4 2022 cash dividend of $0.20 per share
●Quarterly UpdateCorporate
Board declares Q3 2022 cash dividend of $0.20 per share
●Quarterly UpdateCorporate
Board declares Q2 2022 cash dividend of $0.20 per share
▲Quarterly UpdateCorporate
Board declares Q1 2022 cash dividend of $0.20 per share
Unlock the full MTEX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MTEX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all MTEX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the MTEX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MTEX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every MTEX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MTEX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
JOBE LARRY ADirectorBuy 2,803 70,000 held$4.12 05/20/2026
Unlock the full MTEX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in MTEX for Q3 2026.
Unlock every fund holding MTEX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MTEX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MTEX ownership
Insider and institutional ownership, quarter by quarter.

MTEX Short Interest

Shares sold short, counted twice a month.

1.47%
Short % of Float
of tradable shares sold short
11.5K
Shares Sold Short
-0.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
45.3K
Avg Daily Volume
the average used for days to cover
Unlock MTEX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock MTEX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MTEX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MTEX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MTEX ranks across every disease it competes in

Competitive Position is a premium feature
See how MTEX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MTEX News

MTEX
Nov 12, 2026
MTEXGeneral
▼ -29.8%on this news· ran to -66% by day 3

Mannatech Reports Financial Results for Third Quarter 2026

Mannatech reported third quarter 2026 financial results, showing net sales of $24.9 million, down $4.3 million from the previous year. The company experienced a significant income tax benefit of $10.9 million, leading to a net income of $8.9 million. However, operational income dropped to $0.3 million, reflecting challenges in sales and recruitment.

Read more →
MTEX
Aug 12, 2026
MTEXGeneral
▲ +21.3%on this news

Mannatech Reports Financial Results for Second Quarter 2026

Mannatech reported a net sales increase of $1.0 million for Q2 2026, totaling $26.7 million. The gross profit margin rose to 76.9%, and the company achieved an operating income of $1.0 million, reversing a loss from the previous year. However, cash reserves fell by 2.4%, and the number of independent associates declined.

Read more →
MTEX
May 14, 2026
MTEXGeneral
▼ -8.8%on this news

Mannatech Reports Financial Results for First Quarter 2026

Mannatech announced its financial results for the first quarter of 2026, highlighting the impact of trade policy changes on its cost structure. The company also provided non-GAAP financial measures to offer investors additional insights into its performance. However, operational constraints may hinder efforts to manage increased costs.

Read more →
MTEX
Apr 17, 2026
MTEXGeneral

Mannatech Reports Financial Results for Fourth Quarter and Year Ended 2025

Mannatech reported a challenging financial year for 2025, with net sales declining to $108.0 million, down 8.3% from 2024. The company faced significant losses, recording a net loss of $15.2 million, largely due to tax provisions and operational challenges. Despite reduced expenses, the impact of foreign exchange and a new ordering system hindered sales growth.

Read more →
MTEX
Nov 12, 2025
MTEXGeneral

Mannatech Reports Financial Results for Third Quarter 2025

Mannatech reported its third quarter 2025 financial results, revealing net sales of $29.2 million, down 8.1% from the previous year. Despite a decline in sales, gross profit margin increased to 76.4%, and net income improved to $1.9 million. The company also noted a significant drop in cash reserves and a decrease in new associate recruitment.

Read more →
MTEX
Aug 12, 2025
MTEXGeneral
▲ +14.7%on this news

Mannatech Reports Financial Results for Second Quarter 2025

Mannatech reported a net sales decline of 7.4% in Q2 2025, totaling $25.7 million. The gross profit margin decreased to 73.6%, attributed to rising freight costs and sales promotions. The company experienced a net loss of $4.3 million, significantly higher than the previous year's loss of $0.6 million.

Read more →
MTEX
Jun 26, 2025
MTEXGeneral

Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

Mannatech has promoted Peter Griscom to Chief Operating Officer effective July 1, 2025. With over a decade of experience in direct selling and consumer goods, Griscom aims to enhance operational efficiencies. His previous roles include senior vice president of global operations and product innovation. The CEO believes this promotion will benefit the company's future.

Read more →
MTEX
Jun 5, 2025
MTEXGeneral

Mannatech Announces Results of Annual Shareholders’ Meeting

Mannatech held its annual shareholder meeting on June 3, 2025, where all proposals were approved. Shareholders elected J. Stanley Fredrick and Tyler J. Rameson to the Board of Directors. The appointment of BDO USA, P.C. as the accounting firm for 2025 was ratified. Additionally, the compensation of executive officers was approved.

Read more →
MTEX
May 21, 2025
MTEXGeneral

Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

Mannatech premiered a documentary on Steve Edwards, who holds the world record for 1,000 marathons. The film highlights his use of the company's Glycan Replenishment Therapy to support recovery and longevity. Edwards credited the supplements for enabling his endurance into his 60s despite genetic challenges.

Read more →
MTEX
May 13, 2025
MTEXGeneral

Mannatech Reports Financial Results for First Quarter 2025

Mannatech reported a net loss of $1.5 million for Q1 2025, a significant decline from a net income of $1.2 million in Q1 2024. Net sales fell to $26.6 million, down 9.6% year-over-year, primarily due to reduced demand in Asia. The company also experienced a decrease in commission expenses and selling costs, but overall profitability remains challenged.

Read more →
MTEX
Mar 26, 2025
MTEXGeneral

Mannatech Reports Fourth Quarter 2024 Financial Results

Mannatech reported its fourth quarter 2024 financial results, showing net sales of $29.0 million, down 11.3% from the previous year. Despite the decline in sales, the company achieved a net income of $2.3 million, an improvement from a loss in Q4 2023. Cost management led to a reduction in selling and administrative expenses, contributing to a positive operating income.

Read more →
MTEX
May 25, 2023
MTEXGeneral

Mannatech Declares First Quarter 2023 Dividend

Mannatech, Incorporated has announced a cash dividend of $0.20 per share for the first quarter of 2023, scheduled for payment on June 29, 2023. This declaration signifies the company's dedication to providing value to its shareholders and promotes long-term investment. The company, which has been in operation for over 25 years and is active in 25 markets, emphasized its commitment to enhancing lives through health and wellness products. However, the announcement included forward-looking statements that caution investors about various potential risks and uncertainties facing the company.

Read more →
MTEX
May 23, 2023
MTEXGeneral

Mannatech Announces New Tiered Affiliate Program Pre-Launch

Mannatech, Incorporated (NASDAQ MTEX) has announced the anticipated launch of its new tiered affiliate program on June 16, 2023, through a wholly owned subsidiary named Trulu. This program aims to innovate in customer acquisition and retention while leading with improved product offerings such as the AMPM powders, designed to support various aspects of health. Mannatech, which has been operational for over 25 years and serves 25 markets, is committed to providing high-quality health products and adapting to the gig economy. The announcement emphasizes the potential for enhanced market share and profitability.

Read more →
MTEX
Apr 18, 2023
MTEXGeneral

Mannatech Announces Formation of Subsidiary to Serve as Innovation Hub

Mannatech, Incorporated (NASDAQ: MTEX) has announced the establishment of a wholly owned subsidiary intended to serve as an innovation hub, named Trulu. This new entity is designed to capitalize on the growing gig economy by providing a simplified business opportunity focused on health and wellness. While operating separately from Mannatech, Trulu will still collaborate closely with the parent company, emphasizing the ongoing commitment to Mannatech's existing business model while exploring new growth avenues. The initiative highlights Mannatech's recognition of the necessity to adapt its business strategies to remain competitive in the marketplace.

Read more →
MTEX
Mar 6, 2023
MTEXGeneral

Mannatech Declares Fourth Quarter 2022 Dividend

Mannatech, Incorporated has announced that its Board of Directors declared a cash dividend of $0.20 per share of common stock. This dividend is set to be paid on March 30, 2023, to shareholders on record as of March 16, 2023. The company emphasizes its commitment to rewarding shareholders and promoting long-term investment. Mannatech has been operational for over 25 years, focusing on health and wellness products through a global network.

Read more →
MTEX
Nov 11, 2022
MTEXGeneral

Mannatech Declares Third Quarter 2022 Dividend

MEDIA CONTACT Donna Giordano 972-471-6512 ir mannatech.com Mannatech Declares Third Quarter 2022 Dividend (Flower Mound, Texas) November 11, 2022 - Mannatech, Incorporated (NASDAQ MTEX), a global health and wellness company committed to transforming lives to make a better wor

Read more →
MTEX
Sep 20, 2022
MTEXGeneral
▲ +14.1%on this news

Mannatech Announces Share Repurchase Program

MEDIA CONTACT Donna Giordano 972-471-6512 ir mannatech.com Mannatech Announces Share Repurchase Program FLOWER MOUND, Texas (BUSINESS WIRE) September 20, 2022 - Mannatech, Incorporated (NASDAQ MTEX), ("Mannatech"), today announced that its Board of Directors has approved a sh

Read more →
MTEX
Aug 30, 2022
MTEXGeneral

Mannatech Declares Second Quarter 2022 Dividend

MEDIA CONTACT Donna Giordano 972-471-6512 ir mannatech.com Mannatech Declares Second Quarter 2022 Dividend (Flower Mound, Texas) August 30, 2022 - Mannatech, Incorporated (NASDAQ MTEX), a global health and wellness company committed to transforming lives to make a better worl

Read more →
MTEX
Jun 3, 2022
MTEXGeneral

Mannatech Declares First Quarter 2022 Dividend

MEDIA CONTACT Donna Giordano 972-471-6512 ir mannatech.com Mannatech Declares First Quarter 2022 Dividend (Flower Mound, Texas) June 3, 2022 - Mannatech, Incorporated (NASDAQ MTEX), a global health and wellness company committed to transforming lives to make a better world, a

Read more →
MTEX
Mar 4, 2022
MTEXGeneral

Mannatech Declares Fourth Quarter 2021 Dividend

MEDIA CONTACT Donna Giordano 972-471-6512 ir mannatech.com Mannatech Declares Fourth Quarter 2021 Dividend (Flower Mound, Texas) March 4, 2022 - Mannatech, Incorporated (NASDAQ MTEX), a global health and wellness company committed to transforming lives to make a better world,

Read more →

About Mannatech, Incorporated

Flower Mound, TX 170 employees mannatech.com
Headquarters1410 LAKESIDE PARKWAY, FLOWER MOUND, TX, 75028
BIOPHARMAWATCH ELITE
Trade the next MTEX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime